J&J Muscles Into CAR-T Field: Initiates Myeloma Studies

 
• By John Davis

An autologous CAR-T therapy in development by Janssen and Legend Biotech is expected to kick-off US clinical studies in the second half of 2018, adding to the race to apply the new technology to multiple myeloma.

SC1805_Horse Racing_ 657743737_1200.jpg
It's a race to the finish for a CAR-T multiple myeloma therapy • Source: Shutterstock

More from Clinical Trials

More from R&D